Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant high blood pressure, announces the availability of its Letter to Shareholders.
The Letter to Shareholders is available on the Quantum Genomics website, www.quantum-genomics.com, section Investors / Letters to Shareholders.
Upcoming meetings
2020 annual results: March 25, 2021 after market close
General Meeting of Shareholders: June 24, 2021
Half-year results 2021: October 6, 2021 after market close
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the mechanism of inhibition of cerebral Aminopeptidase A (Brain Aminopeptidase A Inhibition or BAPAI). The only company in the world to pursue this innovative approach directly targeting the brain, it is based on more than twenty years of research work from the University of Paris-Descartes and the INSERM / CNRS laboratory led by Dr. Catherine Llorens-Cortes at France secondary school. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant arterial hypertension (around 30% of patients are poorly controlled or have failed treatment), and Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the US OTCQX market (symbol: QNNTF).
Contact:
Dan Ferry
Tel: +1 (617) 535-7746
Email: Daniel@lifesciadvisors.com
(C) 2021 Electronic News Publishing, source ENP Newswire